Director · Tarsus Pharmaceuticals, Inc. · Tarsus Pharmaceuticals, Inc. — Stock Option (right to buy)
Side
A
Value
—
Shares
3,837
Price
—
Executed
Jun 25, 2026
Disclosed
Jun 29, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 25 executedJun 29, 2026 disclosed
TARS · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Tarsus Pharmaceuticals, Inc. — Stock Option (right to buy)
Ticker
TARS
Shares
3,837
Price per share
$0
Execution date (reported)
Jun 25, 2026
Owned after transaction
3,837 shares
Days from execution to publication
4
What this establishes
Goldberg Andrew D. filed this Form 4 reporting a grant or award of TARS on Jun 25, 2026. It became public on Jun 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Goldberg Andrew D.cik:0001827722
Issuer
Tarsus Pharmaceuticals, Inc.cik:0001819790
Revision history · 0
No field has changed since this record was first ingested.
